

0001213900-25-0102776-K Inspira Technologies OXY B.H.N. Ltd 2025020520250205085017085018085018 0
0001213900-25-010277 6-K 3 20250205 20250205 20250205 Inspira Technologies OXY B.H.N. Ltd 0001837493 3841
000000000 L3 1231 6-K 34 001-40303 25591038 HATIDHAR 2 11TH FLOOR RA'ANANA L3 4366504 972-9-9664488
HATIDHAR 2 11TH FLOOR RA'ANANA L3 4366504 6-K 1 ea0230007-6k_inspira.htm REPORT OF FOREIGN PRIVATE
ISSUER Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 6-K Â
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES
EXCHANGE ACT OF 1934 Â For the Month of February 2025 Â Commission File Number: 001-40303 Â Inspira
Technologies Oxy B.H.N. Ltd. (Translation of registrantâ€™s name into English) Â 2 Ha-Tidhar St. Raâ€™anana
4366504, Israel (Address of principal executive office) Â Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F: Â â” Form 20-F Â Â Â Â Â Form 40-F Â Â Â
CONTENTS Â On February 5, 2025, Inspira Technologies Oxy B.H.N. Ltd., or the Registrant, issued a press release
titled â€œInspira Technologies Integrates New Oxygenation Indicator into AI-Powered HYL A Blood Sensor,â€ a copy of
which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form 6-K. Â The first, second, third, and
fifth paragraphs and the section titled â€œForward-Looking Statementsâ€ in theÂ press release are incorporatedÂ by
reference into the Registrantâ€™s Registration Statements on Form F-3 (Registration Nos.Â 333-266748Â andÂ 333-
284308) and FormÂ S-8 (Registration Nos.Â 333-259057Â andÂ 333-277980), filed with the Securities and Exchange
Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted,
to the extent not superseded by documents or reports subsequently filed or furnished.Â Â ExhibitÂ No. Â Â 99.1 Â
Press Release issued by Inspira Technologies Oxy B.H.N. Ltd. on February 5, 2025, titled â€œInspira Technologies
Integrates New Oxygenation Indicator into AI-Powered HYL A Blood Sensor.â€ Â 1 Â Â SIGNATURES Â Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized. Â Â Inspira Technologies Oxy B.H.N. Ltd. Â Â Â Date:
February 5, 2025 By: /s/ Dagi Ben-Noon Â Â Name:Â Dagi Ben-Noon Â Â Title: Chief Executive Officer Â Â 2 Â Â
EX-99.1 2 ea023000701ex99-1_inspira.htm PRESS RELEASE ISSUED BY INSPIRA TECHNOLOGIES OXY B.H.N. LTD.
ON FEBRUARY 5, 2025, TITLED "INSPIRA TECHNOLOGIES INTEGRATES NEW OXYGENATION INDICATOR INTO AI-
POWERED HYL A BLOOD SENSOR." Exhibit 99.1 Â Â Inspira Technologies Integrates New Oxygenation Indicator into
AI-Powered HYL A Blood Sensor Â Inspira Technologies develops its innovative AI-powered HYL A technology with
advanced blood testing capability, enabling continuous monitoring of tissue oxygenation and early hypoxia detection;
Company expects to release preliminary clinical results for the sensor in the near future Â Raâ€™anana, Israel -
February 5, 2025 â€“ Inspiraâ„¢ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (â€œInspiraâ€ or the â€œCompanyâ€),
a pioneer in breakthrough life-support technology, today announced the integration of a next-generation oxygenation
indicator into its AI-powered HYL Aâ„¢ blood sensor technology, designed to enable the rapid detection of critical
oxygen-related conditions without the need for intermittent blood draws. Â We believe that the integration of this
advanced indicator represents a significant enhancement in critical care monitoring. The technology is designed to
provide data through real-time and continuous monitoring of oxygenation therapy, enabling the rapid detection of tissue
hypoxia and the early warning of respiratory complications. The advanced AI-powered system is designed to indicate
the level of lung function and to monitor vital blood parameters, positioning HYL A as a potential game-changer in the
\$2.5 billion point-of-care testing and arterial blood gas analyzer market. Â Clinical validation of the enhanced HYL A
blood sensor, with its new oxygenation indicator, is currently underway at Sheba Medical Center, ranked among the
worldâ€™s top 10 smart hospitals by Newsweek. The Company is optimistic about the ongoing evaluations and expects
to share preliminary clinical results in the near future. The non-invasive technology utilizes sophisticated optical
sensors and machine-learning algorithms to deliver continuous monitoring of blood parameters and oxygen levels, with
a U.S. Food and Drug Administration (â€œFDAâ€) submission for regulatory clearance anticipated for the second half
of 2025. Â â€œThis advancement marks an important step in transforming critical care monitoring,â€ said Dagi Ben-
Noon, chief executive officer of Inspira. â€œThe integration of this new oxygenation indicator into HYL A will enable
healthcare providers to monitor and respond to changes in tissue oxygenation in real-time. We continue to advance in
our clinical evaluation program and look forward to sharing preliminary clinical results with the public in the near
future, which we hope will further validate the HYL Aâ€™s unique technological offering and superiority over traditional
blood sensors in the market.â€ Â The addition of advanced oxygenation monitoring capabilities further strengthens
HYL Aâ€™s position as a comprehensive blood monitoring solution. When combined with the FDA-cleared INSPIRA
ART100 system, this technology aims to provide a more complete approach to patient care by enabling continuous, non-
invasive monitoring while maintaining consciousness during treatment. Â Â Â About Inspira Technologies Â Inspira
Technologies is an innovative medical technology company in the life support and respiratory treatment arena. The
Company has developed a breakthrough Augmented Respiration Technology (INSPIRAâ„¢ ART), a groundbreaking
device poised to revolutionize the \$19 billion mechanical ventilation market. With 20 million intensive care unit patients
with acute respiratory failure each year, many of whom rely on mechanical ventilators, the INSPIRA ART offers a
potential alternative by elevating and stabilizing decreasing oxygen saturation levels in minutes without a ventilator,
with patients being awake during treatment. The INSPIRA ART is being equipped with a clip-on HYL Aâ„¢ blood sensor,
a real-time continuous blood monitoring technology, aiming to alert physicians of changes in a patientâ€™s condition
without the need for intermittent actual blood samples, aiming to support physicians in making informed decisions. Â
For more information, visit: <https://inspira-technologies.com> Â Forward-Looking Statement Disclaimer Â This press
release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These
forward-looking statements are based on the current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause actual results to differ materially from those described
in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the
prospective benefits and function of the HYL A blood sensor, the belief that the integration of this advanced indicator
represents a significant enhancement in critical care monitoring, the prospective FDA regulatory clearance submission,
the belief that this development marks an important step in transforming critical care monitoring, the expected release
of preliminary clinical results, the belief that the integration of this new oxygenation indicator into HYL A enables
healthcare providers to monitor and respond to changes in tissue oxygenation in real-time, and the belief that the
addition of advanced oxygenation monitoring capabilities further strengthens HYL Aâ€™s position as a comprehensive
blood monitoring solution. These forward-looking statements and their implications are based solely on the current
expectations of the Companyâ€™s management and are subject to a number of factors and uncertainties that could
cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise

required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at www.sec.gov. Company Contact Inspira Technologies Media Relations Email: info@inspirao2.com Phone: +972-9-9664485 Capital Markets & Investor Contact Arx | Capital Markets Advisors North American Equities Desk inspira@arxadvisory.com GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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j56G*UX3@[-7 M5TULTTVI1E&2;4DSTZ56G7I4ZU*2G3JP4X26SC):>.:U33U4E)-73"BOY[_V MNO\ @JW^T5K_.U+XC_8<_X)K_!? 3/C/_ "3Q?%3Q_K!\U#PQX0U.S>T36 M-*L;;;5O#NAV47AJ>\M]+U[Q/XIUR/3\$(13/X=L-)O+ZV\$MS()^Q9>_%!;C MX]^' P#AM+2?A18_-]{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n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

P[IL[!Y+!&#.HO;[6N9 _]VD:1I6@:3IF@Z%IMCHVB:)IUEI M&CZ1I=I!8:9I6E;;;16>GZ;IUC:I%;6=C8VD,-
K:6EO"!;\4<,2)&BJ/Y5 M_P#@Y2^!GQF^&/BG]BK_(*Y?L]^!GQ5XM_8&^(-K/4=!MH9;C=+\[SQ]I
M7B+3]9?"^GZQ;ZUX7\7W2B3^S=&\>'6)4CT_3-1N(_P!]/V(?VZ_V M<_\n
@H%/#_#/QR_9V\=Z3XDTG5M.L7\4>\$FOK0>-OAKXCFMT?4/!_CSP^_DK7_MVB:UIESYUL))H1I^KPQ)JFB7>H:5(?
B%#XQ\Z_DA)9XO#VE>(K_M7OX7?YVAT^_G^8G/0?][9/[;/.!GP7\2_+'+I+XC:)X(\+Z'IM_<:1H\] M[;XN\>:U:V[2V?
A+P%X;;R:CXD\1ZK/Y5I;VMG\$;;S\[[?J]UIVE6]W?V_\ MD7_!M!\:O'_[2\ P59_X*F?M_?%#PW?^#?&_P_9O_A_P"
(^J>\$=3M;JRO/_M"^G^*?B7+J7A;P^]O?0P7?DZ1X0ET"PLYH4-Y906]Z@,=PC'7)Z&+CD?&N(
M:G'!3P6'IIRO&%;\$0QV'DG33LINC32DIM7Y54=N6,FF^5R4;>_\ P"O7]LC0M=\2_LP?&C0_#.FZQJ^
MO:AX.N(,T_P_I\NK:Y/<17ME<;M)TR&&YE"U"@CB>YMK-+>X-Q+"L7D3!C&
MWR%X"_\$3Q/XXN9+F7XV:KX!\6_M4>&O\$^K_\$76M+UWX1>.O'_AC3?V>O\$5_MAJ.F^_-]#T#3O!MQ;?
#3PMXN\^"/#6@RR>'O#EIKSE[.:4)(WU;5/N'!IKX_MCZ]\n
(O@)\4OB5X8.FKKW@[PM=:OIDFL65SJ6EP7\$<[O#]IOM/L[FSNKZ"VCF_M>X:TMJ":X,8ACD#.*\;;J_J_PW\-"NFWOC76?
%OQCFU#0?%?CV3Q1\OA>_M>%K+2?_WA7Q%H'A;6K[5?#FN^)I-3A_L35=?L1+][G>YU'5[>=YM*TJ]X%LRM\ ML>X?
&G@J'X\Z;X+\37?C_\$KQ+XFUV/P?X5^_,?@QO"G[2NFV'AGQ;??\$*>;5_M?BTOB#P]XA%SXPTO2=)CDT\>%/V>
[O1]!USPM>Z%<:K'I^@:<1:;+5+NS^(ZW\MWX8_-U2[&G:I;7=_JD?A_Q-_M:_#>?
0]8T9_%=Q+XDG@0W\IZIKMKJ%X_P"C>H?MB>+"RMROP^>,H>(YO\$ MWQ_)S^!M-\(:7=>+=.U7X::+IGB;Q(U_
/\$J:-%:'PWK&G:UI=Q%K%+3Q!XX(Q>-_MO!7@JZNBK_B-M'2'BSQ1HEYHZZ?9P:5/IUKJGB'0=
(UG5=+U'4X;>@#Y^UCPI\ M9'"E]XP_^"E^+R^%;'XD_M#?^(\C>(/&FN.WA[4OV5]'OO"C0:QJVIW^IWW
MFR_%V[U>3PR]S?7\$=IXP>:'2V@N((DBY?*P)\6_#FFOIALOC[K?@'58OV1_\$M'Q8LK/Q-X^U[QIKD-
WH_Q'M_C(N@76%Z=\$BG6_M&RB2YNHI_J>#]MKX\$7%QJ\$":IKZII8^%4U[>2:%(MC'8?%SPAJ/CO1-5BNOM
M!2ZTWP]X6TG4-4;W%KYQ\,QVSQ74U71?,\$SVVE:1J=CX2UZYCU.U MS2=2\W&DW4/B*ST61"!
J_8Z\=/JOPH\$^_-0@^(UYJET/B]KEMJ_C&S\1_M:N;'0]"^_OB[PSI?AGQ%XSU2?
4X5\6:5I[;=8Q>'[6;O5AINF7\$9FM+"28_M?85?7@O[K;]G+PUX1-%UO2O#?A+1+/_A7>@>'/#VF&W^(.DR>;#X7
MZ=%\---T[5Y9]J2_\>ZSHNB6T7B6'PS>7TVO6&N.LFCW4^KIZ[^SI\4_\$7Q; M\,^.-?\'\$NBW7ARYT3XO?
\$GP7I^A:E86^G:U!>B^%=>?3=+M=-M[/4]8LGUA_M(\$W7EQ8ZC<6=P62;W;RV_H_@****
/GW]JW]G#P7^U[^SG\8/V9OB+JGB/1_M?_QI%Q2CX'\3:KX1N[&Q2V.E:DT+SW&C7>I:JMA!>J8%\$&O\$>K:E_MK%
[>KK">'4T_:Q%)A_MC(0BURQQ5.*C"NKQ;YXQ22;;5EK%F4J%&E_,'9OV./V5_7[O[,WPE_98^%K^*=>!?!S0;[P_X;U?
QK>Z?J'BF]L M_7]7\132:Q>:5IFCZ?/<+>ZURV+A"-.:<[J,(14\16T8Q5DE=O1+ M1:L_('X_P#!%W]F;X*?#W_@H;\n
O# 'CCXRW^B?%)KSQL>_&RYUK7_#%QJ7_MA>7QQ'X]BU1?AQ:->\$;#*24MU^(>LFR_MRW\0/&;3O.>?RIO\@SX7?
&G_M'_!+[P!XDTSQ!XFU7]H[XLVNESPS)X6\:_\$[1]-\Z@D3!GM=6_X0?P;X4\0_MW-I<;52XM[7Q#8QS1;XIA)&Y6OZ<:.*
[])YIF%15E/%U9*NZ;K7FY_M/V5_%_AQ_- "NA>"/_?@K1;'P(X3\)>=&.MM)T'P_MHFFPK;V6FZ9I]HD<%M;P1J.%7=)
(7FE:2:21VZZBBN_J4I3E*OBE*O&?][9.ZYX3\26SRVQN;7XK?M\$OI^KZ9>_EOJ6AZ_I4SFXTC7M
M&O+5];N/WUE>0N23]OZS_P:R_#SPW>:EI'[-O\ P4=_;_K_9V^\$^IW\$TK_"7_M0/'CZUX?L(+EMUQ9:=N)))?TV_P"";\n
MP2TD_P""??QQ_:R^,DGQH_X6D/VUOC3-\7\$V_\ "\$+X4_X5X)?%?Q%3?V%_M_:(\1ZV?\$9\>"S^WFUTC\ 9GG?
91]J\N']=J^IS+B#%4\QKU_JQU186K1P_M"<"",Z,JM#_82A4E[#%4:L(U(U*4X>TC3A)J:E*/*SP,#E-%X.E#&X:/MZ=
M7%-24G&HH5,56]07M*4XMQE"<7RN4DKM65VG^_7_3F_P""&W[#W_!-K7+G_MXD_#?0/\$WQ7^/_HVMW;7_P
?/C1]5EXI\=64>I_KJT?A&UM=/T[0!BZNK/'_MJE_H^F_)%)j=O)+9:EK][8RM;]! ?VM/V:?!'[8O[-_Q?_9B^)&J>)=\\$\"_&_M?
PC<>#?,\$VJ^_#[NQL/\$UCIMS=6EV\^C7FIZ=JUA;WBRV<062ZTV\B",X,1)!_MT117A5L?C<1BHXXVOBJU7%0G"<*)2?
-.\$J4E*GR77)!4Y13A"\$ (PBUI#>_JT\ M+AJ-%X>E1ITZ#C*+IPC;E)6ES6?-)R6CDY.3[K2WP?X" _X)\?!_X>?\'\$^\$
MX)OZ/XD^(%S\%D^"GBWX%#Q/J&J:-)\1CX4\8P:W!]6H?VM!H5OH@UR!->NS_M9W(\BTC:.#S+*4(X?L/V\$?V+?AE_P
\$^OV8_7[*GP?USQGXC\ ?#RZ\57>_MC:O\0-0TO5/%5S)XN\4ZOXMU\$:A>Z-
I&A:*=D.HZS,Q52G6HU*)25+\$8GZY6@W'EJ8JTX^WE:*?/RU)JZ<5:3]W:SCAJ\$: ME.K&E!5*5%X>G-
7YH46U)TU[UN5RBGJF[KVLLMM=VES%+;W,\$LD,T;QNRG^_M:XZ?\&NW[(7B?XH:I\7_P!DCX[?M\$_L%>+-
=GN+C5M)^_OBDCP2C74GG31: M!H\]QI?B#PU823-++_8FF>+DV6N]8=-T>PM8U@K^FJBM,%F6.RZ4Y8+\$U*'
MM4HU8Q<94JL5LJM&I'K1J6Z<]-M:VDDVG.)P>&Q:BL11A5Y'>\$G=3@^O)4@X_MSC?JE*S=FU=)K^=']F/_(-K/V/OA-
\5="^_G[3?Q5^_W[?GQ4*WEMJ'A>[_M_:;4? \"0^"-&OK.5+BSO)!+/?_P#"0/9W4:7%M8>*)=U[04D5))-&EFCB
MEC_1C]G+_@F=\#_V9/VS/VKOVW_WBGXE:I\4/VO4T^/XA^'_ \$NK:#=^!] "C_MTR]M;ZVC\';8>'=-U73T5[.&+;J6LZJJP
QH\$PI7]%)J*UQ&;YGB0: ^WQM:H_MJU^8>I!N\$;;H*I&K[*-*%._%*G#VL(3:I4Z;#O\$KS1;;I=C]B-_I=SX.
MMK:TF=62:WO[HW4I?;\$;PSK/PY\K'/>Z;>_M3SO):%K>3IM(_8Z\+^'M;T""0O&GB:Q^&>D:]\,?&5Y\,9;31;NSUCQM\ (O#
M>B>&!/NN3^)'LDUJVLS9^%_"_ KVBVY^S:QK&A6]UY]I:WFIV-[J]AT4_?""A_M7_@G_P#"GPU_PB,,_B/QEKMAX9TOXV:)?
V&HW.FQQ>*)^,5M=Z:;6>L2VEA_M!.@^&OA'4-0(\>_Y;[%:2QT>E-XUW=!9QVGP[_9,TOP+8>#M/N/&\$>JQ^_ _M'?
ACQEX?N-(^'G@#P/>WVT;V-MI\Q>0S_7=%_'POH7[#GAKPQX<\0>\$O#WC0Z/HW]HZ'K?PZN[#X_M=_#ZV\5^
M:\+_\$'3_B9X9NM0\7PZ-'K/C^ST7Q%I5C:Q;XHEDAOM\$A^RZL_M]_J+ #5E]L^%OP7UOX8M;B+XI>(?
\$\$&H>+/B5XX\=6NH^'_ "EK#XT\3?7\$2^L-_M22Y=K#2X9_#UCX5N[>]&B6&BS0K